The Addition of Etanercept to Standard GVHD Prophylaxis in Patients Undergoing a Full Intensity Allogeneic Hematopoietic Stem Cell Transplant for the Prevention of Transplant Related Complications.
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2017
At a glance
- Drugs Etanercept (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 02 Oct 2012 Planned end date changed from 1 Aug 2012 to 1 Aug 2013 as reported by ClinicalTrials.gov.
- 02 Mar 2010 Planned end date changed from 1 Aug 2010 to 1 Aug 2012 as reported by ClinicalTrials.gov.